Brind.
  1. iRhythm Technologies and Movano, two medical companies, are facing investment scrutiny regarding their services providing ambulatory cardiac monitoring in the US.

An Avalon study found that Zio led to faster diagnoses and lower costs.

2 reports, 2 independent Updated Aug 21
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

An Avalon study found that Zio led to faster diagnoses and lower costs.

Who's involved

What this event is mainly about
Avalon

Keep exploring

Part of

iRhythm Technologies and Movano, two medical companies, are facing investment scrutiny regarding their services providing ambulatory cardiac monitoring in the US. All 1 developments

The entities involved

  • Avalon

    Japanese record label specialized in heavy metal

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Does New AVALON Study’s Results Strengthen the Bull Case for iRhythm Technologies (IRTC)? iRhythm Technologies recently announced the publication of the AVALON study in the American Journal of Manage
  • GlobeNewswireAVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperfo